John Yang, MD
Ophthalmology · Chicago, ILNPI 1942315312
Payments from drug & device makers
Across 90 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- Sun Pharmaceutical Industries Inc.$269
- Novartis$234
- Harrow Eye, LLC$203
- Tarsus Pharmaceuticals, Inc.$195
- Alcon$99
- plus $505 from 12 others
What the payments were for
- Food & beverage$1,98999%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $504 |
| Sun Pharmaceutical Industries Inc. | 11 | $269 |
| Novartis | 12 | $234 |
| Harrow Eye, LLC | 7 | $203 |
| Tarsus Pharmaceuticals, Inc. | 6 | $195 |
| Alcon | 4 | $99 |
| Sight Sciences, Inc. | 4 | $92 |
| Glaukos Corporation | 1 | $89 |
| Aerie Pharmaceuticals, Inc. | 4 | $81 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Oyster Point Pharma, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| NEW World Medical,inc. | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$2,008 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $73,002 |
| LumiganBimatoprost | 82 | $55,513 |
| XiidraLifitegrast | 38 | $34,770 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $15,021 |
| CequaCyclosporine | 12 | $13,918 |
| RhopressaNetarsudil Mesylate | 33 | $12,812 |
| Cyclosporine | 28 | $12,527 |
| Travoprost | 57 | $11,861 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $11,667 |
| TyrvayaVarenicline Tartrate | 17 | $11,157 |
| Restasis MultidoseCyclosporine | 17 | $9,353 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $7,556 |
| Latanoprost | 437 | $7,047 |
| VyzultaLatanoprostene Bunod | 12 | $6,227 |
| Cosopt PfDorzolamide/Timolol/Pf | 15 | $5,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $504 | $157,747228 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $79 | $40,99750 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $269 | $13,91812 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $81 | $12,81233 claims |
| AlconSimbrinza | $99 | $11,66738 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $34 | $11,15717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Manjot GillChicago$1.4M
- Amani FawziChicago$864K
- Sarah SunshineChicago$664K
- Jennifer LimChicago$636K
- Dilraj GrewalChicago$543K
- Ahmad ArefChicago$355K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Armin AfsharChicago$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.